Lynk Pharmaceuticals Competitors and Similar CompaniesClear all

Lynk Pharmaceuticals's competitors and similar companies include Rigel Pharmaceuticals and BridgeBio.
Lynk Pharmaceuticals
Lynk Pharmaceuticals
Lynk Pharmaceuticals (also known as 凌科药业) is a biotech company engaged in the research and development of medicines to treat autoimmune and inflammation diseases, as well as cancer.
Rigel Pharmaceuticals
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
BridgeBio
BridgeBio
BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.
Founding Date
Founding Date
2018
Founding Date
1996
Founding Date
2014
Type
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Hang Zhou Shi, CN HQ
Locations
South San Francisco, US HQ
Locations
Palo Alto, US HQ
Employees
Employees
20
Employees
1633% increase
Employees
24863% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
256 m
Valuation ($)
4.6 b

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$294.3m (FY, 2025)
Revenue (est.)
$502.1m (FY, 2025)
Cost of goods
Cost of goods
N/A
Cost of goods
$19.6m (FY, 2025)
Cost of goods
$21m (FY, 2025)
Gross profit
Gross profit
N/A
Gross profit
$274.7m (FY, 2025)
Gross profit
$481.1m (FY, 2025)
Net income
Net income
N/A
Net income
$367m (FY, 2025)
Net income
($732.9m) (FY, 2025)

Funding

Total funding raised
Total funding raised
$ 60m
Total funding raised
$ 130m
Total funding raised
$ 474.2m
For sources of this data, please see the company profile

View Company Profiles

Rigel Pharmaceuticals
HQ
South San Francisco, US
Employees
163↑ 3% increase

Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.

View company
BridgeBio
HQ
Palo Alto, US
Employees
248

BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.

View company